#nasdaq:pgnx

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Entry into a Material Definitive Agreement

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Entry into a Material Definitive Agreement Item 1.01. Entry into a Material Definitive Agreement. On January 6, 2017, Progenics Pharmaceuticals, Inc. (Progenics) entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald Co. (Cantor), as sales agent, to which Progenics may offer and sell, from time to time, through…